Company News »

Exactech Launches Octane(R) Elevate Peek Spacer System For Lumbar Interbody Fusion Procedures

Business Wire
Share on StockTwits
Published on

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announces that its spine division has launched Octane(R) Elevate, a Poly Ether Ether Ketone (PEEK) spacer system, at the North American Spine Society Annual Meeting (NASS).

With the introduction of Octane Elevate, an innovative, self-distracting lumbar fusion device, surgeons can restore disc height while addressing various anatomical conditions and degrees of degeneration. Octane Elevate is designed to be implanted with less force, potentially reducing incidence of vertebrae and nerve damage. A unique feature of the product’s design and instrumentation allows surgeons to backfill the interbody spacer with autogenous bone graft, which is designed to aid in fusion. Octane Elevate’s versatility is highlighted through its multiple footprint options and heights available in 1mm increments.

“Exactech is focused on developing solutions to make spine surgery less invasive and less traumatic for the patient, and to provide the surgeon with tools that create the opportunity for better and repeatable results,” said Bruce Thompson, Sr. Vice President, General Manager of Spine and Biologics at Exactech. “Octane Elevate is a unique product that we hope will be successful in achieving both goals.”

Created with a goal of simple, intuitive instrumentation, Octane Elevate was designed in collaboration with Charley Gordon, MD to minimize learning curve and surgical time, as well as offer a wide range of interbody options accommodating various anatomical conditions and pathologies.

“I have been very pleased with my clinical results using the Octane Elevate cage. This device is unique in that it is radiolucent and allows a surgeon to place a right sized implant into the intradiscal space from a posterior approach,” said Dr. Gordon. “The cage incorporates a large graft window which facilitates substantial placement of bone and overall I’ve been quite happy with our early clinical results.”

With a successful pilot launch, the addition of Octane Elevate marks another milestone in the continued development of innovative products by Exactech Spine. The system rounds out Exactech’s lumbar interbody offerings enabling surgeons to perform lumbar interbody fusions with a wide range of options.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Share on StockTwits